We’re excited to kick off National ALS Awareness Month. The next 31 days will be dedicated to education about the disease and the work happening around the world to find a cure, and to advocating for people with ALS and their caregivers. This year, we’re asking you to Raise Your Voice to elevate the fight against ALS.
At last week’s 70th Annual American Academy of Neurology (AAN) Meeting in Los Angeles, neuroscientists and neurologists from all over the world came together to present their important work and learn from each other. We are proud that many top ALS researchers we support attended and presented a wide range of research, on topics ranging from environmental risk factors to work leading up to clinical trials.
Neuraltus Pharmaceuticals, Inc. reported disappointing results from its phase II clinical trial studying the impact of an immune regulator, NP001, in people living with ALS who had increased levels of inflammation. The company presented the negative results during the 70th Annual American Academy of Neurology Meeting in Los Angeles.
Dr. Timothy Miller, the David Clayson Professor of Neurology from the Washington University School of Medicine in St. Louis accepted the 2018 Sheila Essey Award for ALS Research April 23 at the American Academy of Neurology 70th Annual Meeting in Los Angeles.
To make cell characteristics visible to the human eye, even under a microscope, scientists normally use chemicals that can kill the very cells they want to observe. Dr. Steven Finkbeiner, director and senior investigator at the Gladstone Institutes in San Francisco (pictured above), recently teamed with computer scientists at Google for a groundbreaking new study funded by The ALS Association Neuro Collaborative through ALS Ice Bucket Challenge donations.
Late last month, Congress passed a $1.3 trillion fiscal year 2018 Consolidated Appropriations spending bill that included a $3 billion increase to funding for medical research to the National Institutes of Health (NIH). Funding to the NIH has increased to $37 billion, the largest bump they have seen in years.
Researchers at Cedars-Sinai in Los Angeles, funded by The ALS Association with ALS Ice Bucket Challenge donations, are dedicated to finding unique avenues for treating ALS. Using animal models, they transplanted specially engineered neural cells into the motor cortex of the brain, the area responsible for muscle movement.
Do you have a passion for making your voice heard and empowering others? Do you want to make a difference in the lives of people with ALS? The 16,000+ advocates for The ALS Association are people living with ALS, family members, friends, caregivers, researchers, scientists, and healthcare professionals who are ready to see a world without ALS.
Lauren Sciences LLC, a private biotechnology company in New York, N.Y., recently received a third grant from The ALS Association to support the continued development of LAUR-301, Lauren Sciences’ novel V-Smart Nanomedicine designed specifically for ALS.
Today, we are happy to be joined by ALS clinician scientist Dr. Peter Creigh from the University of Rochester in Rochester, N.Y., the recipient of the 2018 Clinician Research Training Fellowship in ALS Research. The fellowship is given by The ALS Association, in partnership with the American Academy of Neurology (AAN).